Skip to main content

Table 2 Twenty-five most significant SNPs associated with ER-positive breast cancer in Swedish and Finnish samples

From: Genetic variation of ESR1 and its co-activator PPARGC1B is synergistic in augmenting the risk of estrogen receptor-positive breast cancer

Gene SNP Position Pvaluea Adjusted Pvalueb OR (95% CI)a
PPARGC1B rs741581cd chr5:149182978 4.84 × 10-5 0.033 1.414 (1.197, 1.672)
PPARGC1B rs1012543cd chr5:149157138 9.98 × 10-5 0.067 1.223 (1.105, 1.353)
PPARGC1B rs6895698d chr5:149120455 2.73 × 10-4 0.184 1.225 (1.098, 1.366)
CARM1 rs1529711 chr19:10884434 4.26 × 10-4 0.288 1.229 (1.096, 1.378)
RBM23 rs7469 c chr14:22440037 1.15 × 10-3 0.778 1.248 (1.092, 1.427)
PPARGC1B rs4705365cd chr5:149093146 1.78 × 10-3 - 1.193 (1.068, 1.333)
NCOR2 rs10846670 chr12:123456184 2.67 × 10-3 - 0.872 (0.798, 0.954)
RBM23 rs3811187c chr14:22439134 2.96 × 10-3 - 1.158 (1.051, 1.275)
PELP1 rs4790674 chr17:4529772 3.23 × 10-3 - 1.171 (1.054, 1.3)
PPARGC1B rs2340621d chr5:149122509 4.00 × 10-3 - 1.149 (1.045, 1.262)
CCND1 rs649392cd chr11:69173974 4.43 × 10-3 - 0.877 (0.801, 0.96)
PPARGC1B rs10036538d chr5:149135781 5.51 × 10-3 - 1.156 (1.043, 1.28)
PELP1 rs7214635 chr17:4547769 5.67 × 10-3 - 1.166 (1.046, 1.3)
PPARGC1B rs4705382 chr5:149161559 6.32 × 10-3 - 0.872 (0.791, 0.962)
NEDD4 rs11071224c chr15:53902817 6.32 × 10-3 - 0.764 (0.63, 0.927)
MED13 rs4968469c chr17:57491867 6.90 × 10-3 - 1.145 (1.038, 1.263)
NCOR2 rs12321007 chr12:123449054 7.44 × 10-3 - 1.137 (1.035, 1.25)
MED13 rs9889324c chr17:57481404 8.89 × 10-3 - 1.14 (1.033, 1.258)
NCOR2 rs1794973 chr12:123391545 9.45 × 10-3 - 0.889 (0.813, 0.972)
PPARGC1B rs1422429 chr5:149146627 1.11 × 10-2 - 1.124 (1.027, 1.231)
NCOR2 rs10846666 chr12:123450306 1.17 × 10-2 - 0.867 (0.776, 0.969)
NCOA1 rs17046513 chr2:24817999 1.26 × 10-2 - 1.284 (1.055, 1.563)
NCOA1 rs17046462 chr2:24759054 1.37 × 10-2 - 1.285 (1.053, 1.568)
NCOR2 rs10846667 chr12:123450377 1.40 × 10-2 - 0.895 (0.819, 0.978)
SNW1 rs3759728c chr14:77299912 1.49 × 10-2 - 0.855 (0.753, 0.97)
  1. ER, estrogen receptor; chr, chromosome; OR, odds ratio; CI, confidence interval. aP value and OR were obtained from meta-analysis based on the inverse variance method for two independent datasets. The individual OR was obtained from age-unadjusted analysis in the Swedish sample and age-adjusted analysis in the Finnish sample. bP value was adjusted by Bonferroni correction (n = 675); -, adjusted P > 1. cSNP belongs to the top 25 most significant SNPs associated with ER-negative breast cancer. dSNP was significantly associated with ER-positive breast cancer in both the Swedish and Finnish datasets.